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A B S T R A C T
Microparticles (MPs) derived from acid-sensitive biopolymers enable rapid degradation and cargo
release under acidic conditions, such as at tumor microenvironments, within lysosomal/phagosomal
compartments inside phagocytic cells, or at sites of inﬂammation. One such acid-sensitive biopolymer,
acetalated dextran (Ace-DEX), has tunable degradation rates and pH-neutral degradation byproducts
consisting of dextran, acetone, and ethanol. By studying the degradation proﬁles of Ace-DEX MPs with
varying cyclic acetal coverage (CAC) and dextran molecular weight (MW), we concluded that MPs
composed of low CAC or high MW polymer degraded the fastest at both pH 7.4 and 5.0. To further
understand the properties of this unique polymer, we encapsulated a model drug resiquimod, which is a
toll-like receptor (TLR) 7/8 agonist, into Ace-DEX MPs of different polymer CAC and dextran MW. It was
observed that resiquimod was released faster from MPs of lower CAC or higher MW. By evaluating the
activation of RAW macrophages cultured with different types of resiquimod-loaded Ace-DEX MPs, we
found that MPs of lower CAC or higher MW promoted greater nitrite production and resulted in more
robust cell activation. Our results indicate we can precisely control the degradation proﬁle, release
kinetics, and bioactivity of encapsulated cargos by altering CAC and MW, furthering Ace-DEX MPs'
novelty as a drug carrier.
ã 2016 Elsevier B.V. All rights reserved.
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Acid-sensitive polymers are widely studied and of increasing
interest for drug delivery applications (Jeong and Gutowska, 2002).Abbreviations: MPs, microparticles; MHC, major histocompatibility complex;
PBAEs, poly(ß amino) esters; POEs, poly(ortho esters); APCs, antigen presenting
cells; PLGA, poly(lactic-co-glycolic acid); Ac-DEX, methoxy acetal derivatized
acetalated dextran; Ace-DEX, ethoxy acetal derivatized acetalated dextran; CAC,
cyclic acetal coverage; MW, molecular weight; TEA, triethylamine; NMR, nuclear
magnetic resonance; PVA, poly(vinyl alcohol); PBS, phosphate buffered saline; EA,
ethyl acetate; DMSO, dimethyl sulfoxide; DLS, dynamic light scattering; SEM,
scanning electron microscopy; BCA, bicinchoninic acid based assay; MTT, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; LDH, lactate dehydroge-
nase; LPS, lipopolysaccharide; TLR, toll-like receptor.
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0378-5173/ã 2016 Elsevier B.V. All rights reserved.Because these polymers are stable at neutral environments and
degrade rapidly at lower pH levels, they can provide triggered
release in biological regions of interest where there is an acidic
local environment. Several areas of the body can contain lower pH
regions, such as at tumor tissues (Engin et al., 1995; Lee et al.,
2008), within intracellular compartments (Hu et al., 2007;
Mellman et al., 1986), and at sites of inﬂammation (Ulbrich and
Lamprecht, 2010). Utilizing the natural pH gradient within
biological systems, microparticles (MPs) composed of acid-labile
polymers can enhance biological responses as it allows for targeted
delivery of chemotherapeutic agents to the acidic tumor microen-
vironment (Lee et al., 2008), increased transfection efﬁciency of
DNA vaccine antigens via the pH-gradient in the endocytic
pathway (Little et al., 2004), and localized delivery of immuno-
suppressants to inﬂammatory sites of the gastrointestinal tract
(Makhlof et al., 2009). Moreover, acid-sensitive polymeric carriers
can also reduce the frequency of adjuvant administration (i.e.,
dose-sparing) (Duong et al., 2013; Peine et al., 2013) and promote
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complex (MHC) I and MHC II complexes following phagosomal
escape of encapsulated antigens (Broaders et al., 2009), which are
both advantageous for vaccine applications.
There are currently a few acid-sensitive polymers under
investigation for drug delivery, such as poly(ß-amino) esters
(PBAEs), poly(ortho esters) (POEs), and polyketals (Lee et al., 2009;
Yang et al., 2008). PBAEs have been developed primarily for DNA
vaccine applications (Little et al., 2004, 2005). Due to their acid-
sensitivity, PBAEs particles dissolve rapidly after being phagocy-
tosed by antigen presenting cells (APCs), leading to an increased
transfection efﬁciency and higher levels of dendritic cell activation
compared to poly(lactic-co-glycolic acid) (PLGA) particles. Despite
this promising outcome, PBAEs are associated with potential
toxicity and may cause severe side effects for long-term treatment
(Little et al., 2004, 2005). POEs, on the other hand, have good
biocompatibility and degrade rapidly under acidic conditions.
However, the ortho ester group hydrolyzes quickly in neutral
environments and is stable only under basic conditions (pH 8.4) (Ji
et al., 2014a, 2014b). Polyketals display reduced cytotoxicity and
have high acid sensitivity as suggested by studies performed using
a library of polyurethanes and polyureas containing the same
dimethyl ketal moiety (Paramonov et al., 2008). However, all these
polymers have complex synthesis reactions, which makes them
challenging to be broadly accessible. Therefore, due to the
limitations of existing acid-labile polymeric systems, further work
must be performed to design an easily synthesized polymer with
acid-sensitivity, and minimal toxicity that allows for vaccine and
drug delivery.
One alternative acid-sensitive polymer is acetalated dextran. It
is synthesized from the dextran polysaccharide with the hydroxyl
groups on the glucose backbone replaced by hydrophobic acetals.
Because acetal groups are acid sensitive, acetalated dextran
hydrolyzes more rapidly under acidic conditions into dextran,
acetone, and an alcohol. There are two types of acetalated dextran
polymers depending on their degradation products: Ac-DEX
(methoxy acetal derivatized acetalated dextran) that produces
methanol as the degradation metabolite (Bachelder et al., 2008)
and Ace-DEX (ethoxy acetal derivatized acetalated dextran) that
produces ethanol (Kauffman et al., 2012a). Unlike PLGA and some
polyanhydrides that degrade into acidic byproducts, all degrada-
tion metabolites of acetalated dextran (dextran, acetone, and an
alcohol) are pH-neutral. Thus, hydrolytic degradation of Ac-DEX or
Ace-DEX should not disrupt the local pH environment or harm the
encapsulated payload. This is important because acidiﬁcation of
the local microenvironment, as seen with PLGA hydrolysis, may
result in tissue toxicity and damage to sensitive cargos (Fu et al.,
2000; Na et al., 2003; Sung et al., 2004).
Besides neutral degradation products, acetalated dextran is
advantageous also due to its tunable degradation proﬁles.
Depending on the length of the synthesis reaction, varying degrees
of cyclic or acyclic acetal groups will form. Cyclic acetal groups,
which are the thermodynamic product, form with longer reaction
times and exhibit more hydrolytic stability. On the contrary, acyclic
acetal groups, which are the kinetic product, form with shorter
reaction times and hydrolyze faster. Therefore, the degradation
rate of acetalated dextran can be tuned by varying the length of the
synthesis reaction. Half-lives of Ac-DEX range from minutes to
months (Broaders et al., 2009), with its hydrolysis rate relying on
the reaction time and dextran MW (Kauffman et al., 2012b). Precise
control of the polymer's degradation proﬁle allows for both burst
and sustained cargo release, which makes it an ideal carrier for
desired therapies. Its stability outside cold chain conditions serves
as another advantage of acetalated dextran. Kanthamneni et al.
showed that Ac-DEX MPs containing horseradish peroxidase
remained stable when stored at 20 C, 4 C, 25 C, or 45 C for 3months (Kanthamneni et al., 2012). This property makes acetalated
dextran easy to handle and desirable for use in developing nations.
Micelles and liposomes can be comprised of acid-sensitive
polymers, but they may be hard to manufacture in large scale for
drug delivery applications (Mandracchia et al., 2004; Murthy et al.,
2002; Sawant et al., 2006) and often require cold-chain storage. In
contrast, polymeric MPs can be made in a scalable fashion (Duong
et al., 2013), have been shown to protect cargos outside the cold
chain (Kanthamneni et al., 2012), and can be sized more aptly for
passive targeting of relevant immune cells (Manolova et al., 2008).
In order to demonstrate an acid-responsive platform that has
tunable degradation proﬁles, we characterized the degradation
kinetics of Ace-DEX MPs composed of polymers of different CAC
and MWs. First, we analyzed the hydrophobicity of Ace-DEX
polymers of varying CAC and MW. The polymers were then
formulated into MPs, which were evaluated for size and
morphology. The degradation properties of these MPs were
investigated for their acid-sensitive degradation characteristics
and the ability to tune degradation rate with CAC and MWs. Lastly,
we examined the effect of tunable degradation proﬁles on the
release kinetics and bioactivity of encapsulated cargos. Using
resiquimod (an intraphagosomal toll-like receptor 7/8 agonist) as a
model drug, we characterized the release kinetics of different MP
sets and studied the dependence of degradation proﬁles on drug
bioactivity using RAW 264.7 macrophages. Cyto-compatibility of
blank and resiquimod-loaded MPs was also assessed. The aim of
this study is to characterize the tunable degradation kinetics of the
acid-sensitive Ace-DEX polymer based on CAC and MW, and
demonstrate how variability in degradation impacts drug bioac-
tivity and cyto-compatability by changing the release kinetics of
encapsulated cargos.
2. Materials and methods
2.1. Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis,
MO) and used unmodiﬁed unless otherwise noted. Water used in
these experiments was puriﬁed using a Millipore Milli-Q Integral
Water Puriﬁcation System (Billerica, MA). In the presence of acetal-
containing materials, basic water (pH 9.0) was used by the addition
of triethylamine (TEA) (0.01% v/v). Resiquimod was purchased
from Alexis Biochemicals, Enzo Life Sciences (Farmingdale, NY).
Fluorescence and absorbance readings were generated using a
Molecular Devices SpectraMax M2 (Sunnyvale, CA).
2.2. Cell culture
RAW 264.7 macrophages (ATCC, Manassas, VA) were grown and
cultured according to the manufacturer's protocol. Cells were
maintained at 37 C with 5% CO2 and 100% relative humidity.
Culture media consisted of Dulbecco’s Modiﬁed Eagle’s Medium
(Fischer Scientiﬁc, Pittsburgh, PA), 10% fetal bovine serum
(Hyclone, Pittsburgh, PA), and 1% penicillin-streptomycin (Fischer
Scientiﬁc, Pittsburgh, PA).
2.3. Synthesis and CAC analysis of Ace-DEX polymer
Ace-DEX polymer was synthesized from 10, 71, 500, or
2000 kDa dextran with some modiﬁcations to the previously
described procedure (Kauffman et al., 2012a). To synthesize 10 or
71 kDa Ace-DEX, lyophilized dextran (10 or 71 kDa) and pyridi-
nium p-toluenesulfonate (0.0617 mmol) were dissolved in anhy-
drous dimethyl sulfoxide (DMSO, 10% vol/wt poly). The mixture
was reacted with 2-ethoxypropene (37 mmol; Waterstone, Car-
mel, IN) under nitrogen gas at room temperature. In order to
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or 1440 min, while the 71 kDa reaction went for 3.2, 25, or
1560 min. To synthesize 500 or 2000 kDa Ace-DEX, lyophilized
dextran (500 or 2000 kDa) and pyridinium p-toluenesulfonate
(0.0308 mmol) were dissolved in DMSO (6.25% vol/wt poly). The
mixture was reacted with 2-ethoxypropene (18.5 mmol). To obtain
a 20%, 40%, or 60% CAC, the 500 kDa reaction continued for 4.4, 10,
or 166 min. The 2000 kDa reaction went for 13.8 or 55.2 min to
achieve a 40% or 60% CAC. 2000 kDa 20% CAC polymer was reacted,
but it could not form particles. At desired time points, the
reactions were quenched with TEA. The quenched reactions were
precipitated with basic water, centrifuged at 14,400 rpm for 10 min
at 4 C (Thermo Scientiﬁc Sorvall Legend XTR, Waltham, MA) to
remove the supernatant. The resulting pellet was then frozen and
lyophilized. To further purify the polymer, the product was
dissolved in ethanol (200 proof) and centrifuged at 14,400 rpm for
10 min at 4 C. The supernatant was precipitated in basic water and
lyophilized for another 2 days to yield Ace-DEX polymer. CAC was
determined using 1H nuclear magnetic resonance (NMR) based on
a previously developed method (Bachelder et al., 2008; Kauffman
et al., 2012a).
2.4. Wettability testing using water contact angle assay
Ace-DEX of various dextran MWs and CAC was dissolved in
hexaﬂuoroisopropanol (2% vol/wt poly). The solution was dropped
onto a silicon wafer (test grade, University Wafer). The wafer was
placed on the spin coater (Chemat Technology KW-4A Spin Coater,
Northridge, CA) and rotated at 500 rpm for 5 s and at 2500 rpm for
another 60 s. The wafer was air dried for 30 min at room
temperature before water (15 mL) was added using the sessile
drop method. Images were obtained immediately using a ThorLabs
camera (DCC1645C; Newton, NJ) and analyzed using ImageJ to
determine the contact angle.
2.5. Preparation of blank or resiquimod-loaded Ace-DEX MPs
Ace-DEX MPs were fabricated using a single-emulsion oil/water
(o/w) evaporation method based on a modiﬁed protocol by
Kauffman et al. (Kauffman et al., 2012b). In brief, Ace-DEX (100 mg)
and resiquimod (1 mg) were dissolved in ethyl acetate (1 mL) and
added to poly(vinyl alcohol) (2 mL) (3% wt/wt PVA in phosphate
buffered saline, PBS) in preparation of resiquimod-loaded Ace-DEX
MPs. The mixture was vortexed for 5 s and probe sonicated for 30 s
(amplitude 8, 1 s pulse on, 1 s pulse off; Misonix Ultrasonic Liquid
Processor, Newtown, CT). The emulsion was transferred to a small
beaker containing 0.3% PVA in PBS (20 mL) and stirred for 2 h. The
solution was centrifuged for 45 min at 14,400 rpm at 4 C. The
particle sediment was washed twice with basic water and
lyophilized for 2 days. Blank MPs were fabricated following the
same procedure, except no resiquimod was added. Both blank and
resiquimod-load MPs were made using polymers of different CAC
and MW.
2.6. Encapsulation efﬁciency of resiquimod
Resiquimod encapsulation efﬁciency was determined as
previously described (Duong et al., 2013). Brieﬂy, samples of each
resiquimod-loaded Ace-DEX MP set were prepared in triplicates
and dissolved in dimethyl sulfoxide (DMSO). The solution was
loaded onto a solvent-resistant 96-well plate together with a
calibration curve containing free resiquimod. The amount of
resiquimod was quantiﬁed based on its autoﬂuorescence (260–
360 nm) using a SpectraMax M2 microplate reader (MolecularDevices, Sunnyvale, CA). Blank MPs with corresponding MW and
CAC were used to measure the background signal.
2.7. Size determination of Ace-DEX MPs
The average diameter of Ace-DEX MPs was measured by Mean
Diameter by Number using dynamic light scattering (DLS)
following a previously described protocol (Duong et al., 2013).
Ace-DEX MPs were resuspended in basic water (33.3 mg/mL) and
sized using a Brookhaven NanoBrook 90Plus Zeta Particle Size
Analyzer (Holtsville, NY).
2.8. Scanning electron microscopy (SEM)
Ace-DEX MPs were observed and characterized by; Hitachi s-
4300 Cold Field Emission. SEM samples were prepared by
mounting MPs directly onto the SEM pin stub using carbon tape.
The samples were sputter-coated with a 7 nm layer of palladium/
gold alloy before imaging (Kauffman et al., 2012a; Kauffman et al.,
2012b).
2.9. Endotoxin analysis
All Ace-DEX MPs were prepared using endotoxin free beakers
and stir bars, which were cleaned by soaking in 1 M sodium
hydroxide solution overnight. Solutions were prepared fresh on the
day of particle fabrication. An endotoxin assay was conducted to
conﬁrm the absence of endotoxin of all Ace-DEX MPs. To perform
the assay, MPs were resuspended in nanopure water (1 mg/mL)
and incubated at 4 C overnight. They were centrifuged at
14,800 rpm for 10 min, and supernatant was used for the assay
using the Pierce LAL Chromogenic Endotoxin Quantitation Kit
following the manufacturer’s directions (Thermo Scientiﬁc,
Waltham, MA).
2.10. Degradation analysis of Ace-DEX MPs by optical density
measurement
Blank Ace-DEX MPs with different CAC and MWs were
resuspended in either PBS (pH = 7.4) or 0.3 M sodium acetate
buffer (pH 5.0) in triplicates (1.5 mg/mL). Samples were agitated on
a shaker plate (150 rpm) at 37 C. At 0, 0.5, 2, 4, 8, 24, 48, 72, 168,
and 336 h, the solution was vortexed, and its absorbance at 600 nm
was read using a SpectraMax M2 microplate reader (Molecular
Devices, Sunnyvale, CA). The degradation proﬁle of MPs was
determined by comparing their absorbance levels at different time
points to that at 0 h. The percent degradation of each sample is
equal to the difference between its absorbance reading and that at
0 h divided by the absorbance reading at 0 h. The degradation half-
life was deﬁned as the time when 50% of the MPs had degraded.
2.11. Degradation analysis of Ace-DEX MPs by bicinchoninic acid based
assay
Blank 10 kDa Ace-DEX MPs (20%, 40%, and 60%) were
resuspended in either PBS (pH = 7.4) or 0.3 M sodium acetate
buffer (pH 5.0) in triplicates (1.5 mg/mL). Samples were agitated on
a shaker plate (150 rpm) at 37 C. At 0, 0.5, 2, 4, 8, 24, 48 and 72 h
the solution was vortexed, and an aliquot (120 mL) was collected.
The aliquots were centrifuged at 14,800 rpm for 15 min. Superna-
tant (100 mL) was transferred to a 96-well polystyrene plate and
stored at 20 C. After the last time point, samples were analyzed
using a microplate reductometric bicinchoninic acid based assay
(BCA) following the manufacturer’s guideline (Micro BCA Protein
Assay Kit; Thermo Scientiﬁc, Waltham, MA). This assay measures
the amount of degradation product dextran in the supernatant
Table 1
Relative cyclic acetal coverage (CAC) analysis of acetalated dextran polymer (Ace-
DEX) synthesized from dextran with various molecular weights (MW) as
determined by 1H NMR.
Dextran MW (kDa) Reaction Time (min) Target CAC (%) Actual CAC (%)
10 5.2 20 18
52.6 40 41
1440 60 61
71 3.2 20 19
25 40 37
1560 60 61
500 4.4 20 20
10 40 36
166 60 59
2,000 13.8 40 43
55.2 60 60
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normalizing its reading at a certain time point to that of the
respective MP set at pH 5 at the last time point when it was fully
degraded.
2.12. Release kinetics of resiquimod-loaded Ace-DEX MPs
Resiquimod-loaded Ace-DEX MPs with different CAC and MW
were resuspended in either PBS (pH = 7.4) or 0.3 M sodium acetate
buffer (pH 5.0) in triplicates (1.5 mg/mL). Samples were agitated
on a shaker plate (150 rpm) at 37 C. At 0.5, 2, 4, 8, 24, 48, 72, 168,
and 336 h, the solution was vortexed, and an aliquot (170 mL) was
collected. The aliquots were centrifuged at 14,800 rpm for 15 min.
Supernatant (150 mL) was transferred to a 96-well polystyrene
plate, combined with 30 mL ethanol, and stored at 20 C. At the
last time point (hour 336), a sample (150 mL) was removed from
the homogenous suspension and treated with 30 mL ethanol to
degrade any remaining MPs. This sample contained the total
amount of resiquimod (100% released). The amount of resiquimod
in the supernatant was quantiﬁed based on its autoﬂuorescence
(260–360 nm) using a SpectraMax M2 microplate reader (Molec-
ular Devices, Sunnyvale, CA). The percentage of resiquimod
released was calculated relative to the ﬂuorescence of the
respective MP set after complete degradation at the last time
point.
2.13. Cell viability analysis
Viability of RAW 264.7 macrophages after incubation with
different Ace-DEX MPs was studied using a 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cells
were seeded overnight in a 96-well plate at a density of 40,000
cells per well. Various Ace-DEX MPs (10, 71, 500, or 2000 kDa with
20%, 40%, or 60% CAC) were resuspended in culture media and
added on the next day (0.0625, 0.125, 0.25, 0.5, and 1 mg/mL). After
24 or 48 h incubation, MTT assay was performed to examine cell
viability. Brieﬂy, culture media in each well was replaced with a
solution of MTT reagent in fresh media (0.6 mg/mL, 170 mL). The
plate was incubated at 37 C for around 1 h until purple formazan
crystals formed. The supernatant was replaced with isopropanol
(200 mL), and the solution was pipetted up and down to dissolve
the crystals. The plate was read at 560 and 670 nm using a plate
reader. Background absorbance at 670 nm was subtracted from all
560 nm readings. Cell viability was determined by comparing the
readings of the treated groups to those of the negative (media-
only) and positive (10% v/v Tween 80) controls. Signals of positive
controls were subtracted from all readings to obtain background-
adjusted values. Percent viability was calculated to be the result of
the adjusted-reading for MP-treated cells divided by the adjusted-
reading for the negative control.
2.14. Cytotoxicity analysis
Cytotoxicity of various Ace-DEX MPs on RAW 264.7 macro-
phages was evaluated using a lactate dehydrogenase (LDH) assay
(Pierce LDH Cytotoxicity Assay Kit; Thermo Scientiﬁc, Waltham,
MA). Cells were seeded overnight in a 96-well plate at a density of
40,000 cells per well. Ace-DEX MPs (10, 71, 500, or 2000 kDa with
20%, 40%, or 60% CAC) were resuspended in culture media and
added on the next day (0.0625, 0.125, 0.25, 0.5, and 1 mg/mL). After
24 or 48 h incubation,100 mL media was transferred to a 96-well V-
bottom plate, which was then centrifuged at 4200 rpm for 10 min
at room temperature. Supernatant (50 mL) was transferred to a
solvent-resistant 96-well microplate and analyzed in accordance
with the manufacturer’s protocol.2.15. Nitrite production analysis
Bioactivity of various resiquimod-loaded Ace-DEX MPs on RAW
264.7 macrophages was evaluated using the nitrite production
assay (Griess Reagent System; Promega, Madison, WI). Cells were
seeded overnight in a 96-well plate at a density of 40,000 cells per
well. Resiquimod-loaded Ace-DEX MPs (10, 71, 500, or 2000 kDa
with 20%, 40%, or 60% CAC) were resuspended in culture media and
added on the next day. Particle concentrations (around 0.21 mg/
mL) were adjusted based on their resiquimod encapsulation
efﬁciency so that the ﬁnal resiquimod concentration was the same
across all groups (0.15 mg/mL). Media-only, free resiquimod
(0.15 mg/mL), and lipopolysaccharide (LPS, 100 ng/mL) were
included as controls. Blank Ace-DEX (10 kDa, 60%) MPs were
included as a negative control. This MP set was selected because its
correspondent resiquimod-loaded MP set required the highest
particle concentration (0.23 mg/mL) in order to achieve the same
resiquimod dose due to its low encapsulation efﬁciency. After 24 or
48 h incubation, 100 mL media was transferred to a 96-well V-
bottom plate, which was then centrifuged at 4200 rpm for 10 min
at room temperature. The supernatant (50 mL) was transferred to a
solvent-resistant 96-well microplate and analyzed following the
manufacturer’s instructions.
3. Results and discussion
3.1. Synthesis and characterization of Ace-DEX polymer and MPs
We targeted 20%, 40%, and 60% CAC for Ace-DEX polymers with
different dextran starting material MWs (10, 71, 500, and
2000 kDa). The actual CAC values for Ace-DEX polymers synthe-
sized for different periods of time are listed in Table 1. Because the
actual CAC typically agreed with the target CAC, for the sake of
clarity, the polymers will be referred to using the target CAC (20%,
40%, or 60%). For example, the shortest reaction 10 kDa Ace-DEX
polymer will be referred to as Ace-DEX (10 kDa, 20%) instead of
Ace-DEX (10 kDa, 18%).
Water contact angle measurements of Ace-DEX polymers with
varying CAC and MW are shown in Fig. 1. There was no strong
correlation between the water contact angle and either polymer
CAC or dextran MW. Ace-DEX polymers with varying CAC and
dextran MW had comparable water contact angles, which
suggested similar levels of hydrophobicity. The contact angles of
Ace-DEX polymers are similar to those of PBAEs. Metter et al.
showed that PBAEs synthesized from isobutylamine and 1,4-
butanediol diacrylate had a contact angle of 66.7, while PBAEs
synthesized from isobutylamine and poly(ethylene glycol)-200
diacrylate or diethylene glycol diacrylate showed a contact angle of
16.2 or 35.5, respectively (Metter et al., 2010). Both Ace-DEX and
Fig. 1. Water contact angles of acetalated dextran polymers of various molecular
weight of dextran starting material and relative cyclic acetal coverage (%). Data are
presented as mean  standard deviation (n = 5).
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is 98 (Zhang and Webster, 2013).
Ace-DEX polymers of varying CAC and MW were than
formulated into MPs, which were characterized for size and
morphology using DLS (Table 2) and SEM (Fig. 2). SEM images of
blank Ace-DEX (40% CAC) MPs of varying MW (10, 71, 500, and
2000 kDa) can be found in Fig. 2. SEM images of MPs formulated
using other CAC (20% or 60%) can be found in Fig. S1. The SEM
micrographs highlight that the MPs’ spherical morphology was not
affected by CAC or dextran MW.
To study the degradation proﬁle of Ace-DEX MPs and its
relationship to polymer CAC and dextran MW, we incubated blank
MPs at pH 7.4 and 5.0. Table 3 displays the degradation half-lives of
eleven MP sets of varying CAC and MW. For MPs with the same
dextran MW, degradation half-life related positively with CAC.
Higher MW MPs underwent slower hydrolysis and demonstrated
longer half-lives. For example, the half-life of Ace-DEX (500 kDa,
20%) MPs was 14.5 h, shorter than 85.5 h of Ace-DEX (500 kDa, 40%)
MPs. The half-life of Ace-DEX (500 kDa, 60%) MPs is reported as
greater than 336 h (the last measurement) in Table 3 because less
than 50% of the MPs were degraded at this ﬁnal time point. The
correlation between half-life and CAC was expected based on
previous studies (Kauffman et al., 2012a), and can be explained by
the greater hydrolytic stability of the thermodynamically-favored
cyclic acetals compared to kinetically-favored acyclic acetals.
When CAC was held constant, degradation half-life of Ace-DEX
MPs was inversely related to dextran MW (Table 3). Higher MW
MPs underwent faster hydrolysis and had shorter half-lives. ForTable 2
Number-weighted mean diameter of blank acetalated dextran (Ace-DEX) micro-
particles (MPs) as determined by dynamic light scattering. MPs were composed of
Ace-DEX polymers of different relative cyclic acetal coverage (CAC) and synthesized
from dextrans of different molecular weights (MW). Data are presented as
mean  standard deviation (n = 5).
Dextran MW (kDa) Ace-DEX CAC (%) Mean Diameter (nm)
10 20 149  67
40 136  15
60 128  7
71 20 180  31
40 130  25
60 148  15
500 20 140  50
40 242  68
60 230  51
2,000 40 159  49
60 190  47example, the half-life of Ace-DEX (10 kDa, 20%) MPs was 58.6 h,
much longer than 28.2 h of Ace-DEX (71 kDa, 20%) or 14.5 h of Ace-
DEX (500 kDa, 20%) MPs. This trend may be due to different
packing densities of polymers with various MWs. Because dextran
with smaller MWs has shorter chains, MPs made from Ace-DEX of
lower dextran MWs were presumably more densely packed. This
makes it harder for water molecules to diffuse into the polymer
matrix, which results in a smaller area being exposed to water and
slower MP hydrolysis. The same trend was observed for PLGA
polymers. Wu et al. suggested that MPs made from PLGA polymers
of higher MW degrade faster because their longer polymer chains
are more likely to get hydrolyzed compared to their lower MW
counterparts. The hydrolysis process was further accelerated due
to autocatalysis of the newly-generated carboxylic end groups (Wu
and Wang, 2001).
Another hypothesis for the correlation between degradation
rate and dextran MW might be irregular acetalation. Typical cyclic
acetal groups form by replacement of two hydroxyl groups on a
single glucose ring. Irregular acetalation could occur when
hydroxyl groups of different glucose units (within or between
dextran molecules) are modiﬁed. This may lead to cross-linking
between separate dextran molecules and entanglement of the
polymer, which leads to changes in its hydrolytic proﬁle. If
different glucose rings of the same dextran molecule are cross-
linked, the Ace-DEX polymer may fold back on itself and become
more loosely packed. When glucose rings of different dextran
molecules are cross-linked, it may be harder for the irregularly
linked chains to pack densely. We hypothesized that both
processes might accelerate the hydrolysis process. Because
polymers synthesized from higher MW dextran have longer
chains, they are affected by the folding to a greater extent, which
leads to faster degradation. Future experiments are needed in
order to conﬁrm this hypothesis. This correlation between Ace-
DEX degradation rate and dextran MW was different than expected
based on previous ﬁndings. Instead of a positive relationship
between the two, Kauffman et al. previously showed that MPs
composed of 10 kDa Ac-DEX degraded faster than those composed
of 71 kDa Ac-DEX (Kauffman et al., 2012b). This could be explained
by different properties of Ac-DEX and Ace-DEX. Although Ace-DEX
shares many characteristics with its analog Ac-DEX, Ace-DEX has
an additional carbon on its acyclic acetal groups, which introduces
additional hydrophobicity and steric hindrance, possibly leading to
different degradation proﬁles.
Besides neutral pH, degradation of Ace-DEX MPs was also
studied at pH 5.0, representative of the acidic condition within
phagosomes of APCs (Ackerman and Simon, 2014; Walters and
Papadimitriou, 1978), in order to illustrate the acid-sensitivity of
the polymer. As seen in Table 3, MPs degraded much faster at pH
5.0 than at pH 7.4. Hydrolysis occurred so rapidly for some Ace-DEX
(10, 71, 500 kDa 20%, 500 and 2000 kDa 40%) MPs that they were
nearly, if not completely, fully degraded by the ﬁrst measurement
(0.5 h). As a result, their half-lives (around 0.25 h) were much
shorter compared to those at pH 7.4. Even the slowest-degrading
Ace-DEX (10 kDa, 60%) MP set had a half-life of 21.9 h, much shorter
than that of its corresponding group at pH 7.4 (>336 h). This faster
degradation rate at pH 5.0 agreed with previous studies and
conﬁrmed the acid sensitivity of acetal hydrolysis (Kauffman et al.,
2012a). This acid-sensitive degradation is advantageous since it
enables quick, localized release of encapsulated therapeutics in
acidic environments for any of the previously mentioned
applications.
To conﬁrm the accuracy of the optical density measurement,
degradation characteristics of Ace-DEX (10 kDa 20%, 40%, and 60%)
MPs were also examined using the BCA assay. Degradation proﬁles
generated by the BCA assay qualitatively and quantitatively
overlapped with those generated by optical density measurements
Fig. 2. Representative scanning electron micrographs of blank acetalated dextran (Ace-DEX) microparticles (MPs). Ace-DEX polymers (40% cyclic acetal coverage) were
synthesized from various dextran molecular weights (MW): (A) 10 kDa, (B) 71 kDa, (C) 500 kDa, and (D) 2000 kDa. Scale bars are 1 mm.
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density assay was used for all degradation measurements in this
study because it provided more reliable readings across different
pH levels and could be used for polymers of different MWs. In the
BCA assay, a copper ion reacts with only the reducing end group of
the dextran molecule (Mann et al., 1992). Because polymers of
higher dextran MW have larger units and fewer terminal groups,
BCA was less reactive to Ace-DEX polymers with a MW larger than
10 kDa. For these reasons, the optical density measurement was
used because it can be applied for varying dextran MWs across
different pH levels. By studying the degradation proﬁles of Ace-
DEX MPs, we concluded one advantage of this system to be the
broad tunability as suggested by the wide range of degradation
rates at both neutral and acidic pH. Degradation proﬁles can be
precisely controlled and easily tuned for the desired therapeutic
purpose by simply changing the dextran MW and/or CAC (i.e.,Table 3
Degradation half-lives of blank microparticles (MPs) composed of acetalated
dextran (Ace-DEX) with different dextran starting material molecular weights
(MW) and relative cyclic acetal coverage (CAC) incubated at pH 7.4 and 5.0. Data are
presented as mean  standard deviation (n = 3). Half-lives of some MP sets are
reported as greater than 336 h, because less than 50% MPs were degraded at this
ﬁnal time point.
Dextran MW (kDa) Ace-DEX CAC (%) Blank MP Degradation Half-Life (hr)
pH 7.4 pH 5.0
10 20 58.6  1.12 0.26  0.0023
40 >336 7.43  0.42
60 >336 21.9  1.90
71 20 28.2  1.04 0.25  0.00037
40 >336 2.91  0.33
60 >336 21.3  2.98
500 20 14.5  0.68 0.25  0.00
40 85.5  0.80 0.26  0.0013
60 >336 21.0  0.53
2,000 40 48.6  2.23 0.25  0.00080
60 >336 11.9  1.49reaction time) of the polymer. Flexibility of this system gives it a
major advantage over other acid-sensitive polymers, such as
PBAEs, POEs, and polyketals, of which degradation proﬁles are less
variable.
Another potential advantage of Ace-DEX MPs is reduced
cytotoxicity. Cytotoxicity of blank Ace-DEX MPs was analyzed by
treating RAW macrophages with MPs of varying CAC and MW and
evaluating it using both a MTT and LDH assay. A MTT and LDH were
used because a MTT illustrates both viability and proliferation
whereas a LDH assay provides cytotoxicity and cytolysis. In
general, increasing MP concentrations led to lower MTT activity
(Fig. 3A). Macrophages incubated for 48 h with low MP concen-
trations (0.0625, 0.125, and 0.25 mg/mL) showed high levels of
cellular metabolic activities (>81%) across all treatment groups
(Fig. 3A). Macrophages treated with Ace-DEX (10 and 71 kDa, 60%)
MPs at 1 mg/mL showed lower levels of metabolic activity. This
dampened activity was observed previously by Reddy et al. where
phagocytosis of a large number of apoptotic cells by macrophages
led to inhibited proliferation (Reddy et al., 2002). Although MPs are
not physiologically the same as apoptotic cells, we believe that
phagocytosed MPs could result in similar outcomes (i.e., inhibited
cell proliferation) as engulfed apoptotic cells. The LDH assay
showed little to no cytotoxicity of Ace-DEX (10 and 71 kDa) MPs at
all concentrations tested (Fig. 3B). For Ace-DEX MPs of higher MW
(500 and 2000 kDa), the relationship between cell viability and MP
concentration was less obvious based on the MTT assay. This might
be because these higher MW MPs degraded faster under acidic
conditions (Table 3), which resulted in macrophages being less
saturated, allowing them to proliferate more. Although Ace-DEX
(500 kDa, 60%) MPs caused 31.3% cell death according to the LDH
assay (Fig. 3B), this should not be a cause for concern as this
concentration (1 mg/mL) is much higher than what is practical for
in vitro experiments (Peine et al., 2013; Peine et al., 2014a).
Moreover, MPs formulated using PBAEs, which is also an acid-
sensitive polymer, exhibits much more severe cytotoxicity, as
Fig. 3. (A) Cellular metabolic activity and (B) cytotoxicity of RAW macrophages incubated with blank acetalated dextran microparticles for 48 h. Data are presented as
mean  standard deviation (n = 3). Groups are indicated by dextran molecular weight and relative cyclic acetal coverage of the acetalated dextran polymer.
N. Chen et al. / International Journal of Pharmaceutics 512 (2016) 147–157 1530.1 mg/mL PBAE MPs resulted in around 60% death of P388D1
macrophages (Little et al., 2005). In a different study, 1 mg/mL
PLGA MPs led to nearly 70% decrease in cellular metabolic activity
in one of ours previous studies (Kauffman et al., 2012a). For a
shorter, 24 h incubation period, RAW macrophages treated with
Ace-DEX MPs of varying CAC and MW generated higher metabolic
activity and showed similar trends as observed for the 48 h
experiment (Fig. S4). Thus, we concluded that blank Ace-DEX MPs
was well tolerated by macrophages under these experimental
conditions.
3.2. In vitro bioactivity of resiquimod-loaded Ace-DEX MPs
After evaluating degradation proﬁles and cytotoxicity of blank
Ace-DEX MPs of varying CAC and MW, we encapsulatedresiquimod as a model drug to further characterize the system.
Resiquimod is an immunomodulatory molecule used in vaccine
formulations as a TLR 7/8 agonist. It has also been used for
treatment of type 2 herpes simplex virus (HSV-2) and human
papilloma (Mark et al., 2007). Unlike TLR 9 expression that is only
limited to plasmacytoid dendritic cells in humans, TLR 7/8
expression is similarly expressed in both mouse and humans, as
well as other species (Applequist et al., 2002). Furthermore,
because TLR 7/8 reside in the phagosome (Bishop et al., 2001;
Borteh et al., 2013; Dockrell and Kinghorn, 2001; Duong et al.,
2013), resiquimod is an ideal drug to study the effects of Ace-DEX
MPs’ degradation kinetics on drug bioactivity after Ace-DEX MPs
are phagocytosed by macrophages (Hoang et al., 2014).
Resiquimod-loaded Ace-DEX MPs were characterized ﬁrst for
size and morphology using DLS (Table 4) and SEM (Fig. 4 and
Table 4
Number-weighted mean diameter of resiquimod-loaded acetalated dextran (Ace-
DEX) microparticles (MPs) as determined by dynamic light scattering. MPs were
composed of Ace-DEX polymers of different relative cyclic acetal coverage (CAC)
and synthesized from dextrans of different molecular weights (MW). Data are
presented as mean  standard deviation (n = 5).
Dextran MW (kDa) Ace-DEX CAC (%) Mean Diameter (nm)
10 20 161  92
40 129  38
60 174  126
71 20 119  12
40 99.6  19
60 135  51
500 20 N/A
40 157  45
60 N/A
2,000 40 156  87
60 N/A
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MPs (Table 2). The SEM micrographs of resiquimod-loaded MPs
highlight that the MPs’ spherical morphology was not affected by
CAC, dextran MW, or resiquimod encapsulation.
Endotoxin levels and resiquimod encapsulation efﬁciency were
then examined for these resiquimod-loaded Ace-DEX MPs. All MP
sets had endotoxin levels below 0.25 EU/mL (Tables S1), which is
the FDA's guideline for sterile water (U.S. Food and Drug
Administration, 2015). Resiquimod encapsulation efﬁciency and
ﬁnal weight loading of Ace-DEX MPs are listed in Table 5. MPs with
similar drug loading (0.65–1.0 mg resiquimod per mg MP) were
formulated for release, cyto-compatibility, and bioactivity studies.
Having similar encapsulation efﬁciency across MP sets avoided the
potential effect of drug loading on the release kinetics of
resiquimod. Because the same resiquimod dose could be achievedFig. 4. Representative scanning electron micrographs of resiquimod (resi)-loaded acet
dextran (Ace-DEX) polymers with 40% cyclic acetal coverage and various dextran molecu
are 1 mm.using similar MP concentrations due to close drug loadings, a
consistent particle to cell ratio across groups was ensured. This was
important because higher particle to cell ratios has been associated
with enhanced drug bioactivity (Duong et al., 2013; Jhunjhunwala
et al., 2009).
Release kinetics of encapsulated resiquimod was characterized
for Ace-DEX MPs of different CAC and MW. At pH 7.4, for MPs of the
same dextran MW (10 and 71 kDa), resiquimod was released faster
from MPs of lower CAC (20% compared to 40%) (Fig. 5A and B). This
inverse relationship between cargo release and polymer CAC can
be explained by the shorter degradation half-lives of MPs of lower
CAC (Table 3). When polymer CAC was held constant (40%), a
higher level of resiquimod was released into the supernatant from
higher MW MPs (Fig. 5C). This correlation between cargo release
and polymer MW resulted from the faster hydrolysis of higher MW
MPs (Table 3). Similar trends were observed under the acidic
environment (pH 5.0), where resiquimod was released faster from
MPs of lower CAC or higher MW due to their faster degradation
(Fig. 5). All MP sets released the drug faster at pH 5.0 compared to
their counterpart under the pH neutral condition, suggesting acid-
sensitivity of Ace-DEX polymer. The difference between resiqui-
mod release proﬁles among various MP sets was smaller under
acidic conditions compared to that at a pH neutral environment.
This may be due to the acid-sensitive nature of Ace-DEX polymer.
Because all Ace-DEX MP sets degraded rapidly at pH 5.0 (Table 3),
the effect of varying CAC or MW on resiquimod release was
minimized. Therefore, release kinetics of encapsulated cargo can
be tuned based on CAC and MW of Ace-DEX MPs, which makes
Ace-DEX an ideal carrier for therapeutic delivery as it enables both
rapid and sustained drug release via the same polymeric platform.
When resiquimod was encapsulated into electrosprayed Ac-DEX
(71 kDa) particles by Duong et al., a similar sustained releasealated dextran microparticles (MPs) (A–D). The MPs were composed of acetalated
lar weights (MW): (A) 10 kDa, (B) 71 kDa, (C) 500 kDa, and (D) 2000 kDa. Scale bars
Table 5
Encapsulation efﬁciency (EE) and ﬁnal weight loading of resiquimod-loaded acetalated dextran microparticles (Ace-DEX MPs). MPs were composed of Ace-DEX polymers of
different relative cyclic acetal coverage (CAC) and dextran molecular weights (MW). Data are presented as mean  standard deviation (n = 3).
Dextran MW (kDa) Ace-DEX CAC (%) Resiquimod EE (%) Resiquimod Loading (mg drug/mg MP)
10 20 6.70  0.77 0.67  0.08
40 6.78  0.36 0.68  0.04
60 6.45  1.91 0.65  0.19
71 20 6.54  1.03 0.65  0.10
40 7.38  1.24 0.74  0.12
60 7.64  1.06 0.76  0.11
500 40 9.78  1.85 0.98  0.19
2,000 40 6.69  4.24 0.67  0.42
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(Duong et al., 2013). This discrepancy may be due to differences in
fabrication methods and varying drug weight loading.
After evaluating the tunable and acid-sensitive release kinetics
of resiquimod-loaded MPs, their cytotoxicity was analyzed on RAW
macrophages using a MTT and LDH assay. For the 24 h incubation,
all treatment groups showed comparable viability and prolifera-
tion levels to cells treated with blank MPs (Fig. 6A). Except for the
LPS-treated positive control, all groups showed larger than 100%
metabolic activity, which was due to increased proliferation. The
higher proliferation level was previously observed by Peine et al.,
where RAW macrophages were treated with resiquimod-loaded
liposomes (Peine et al., 2014b). For the 48 h incubation, treatment
groups showed lower metabolic activity than that observed for
blank MPs, which might result from limited proliferation. Little to
no cytotoxicity was observed for either treatment period as
measured by the LDH assay (Fig. 6B). Thus, resiquimod-loaded Ace-
DEX MPs exhibited similar levels of cyto-compatibility to blank
MPs, which were both better than previously reported with PBAE
MPs, causing a 60% drop in the viability of P388D1 macrophages at
0.1 mg/mL (Little et al., 2005).
We then evaluated the in vitro bioactivity of resiquimod-loaded
Ace-DEX MPs by monitoring the release of pro-inﬂammatory
nitrite by RAW macrophages. Resiquimod-loaded Ace-DEX MPs of
varying CAC and MW resulted in signiﬁcantly higher levels ofFig. 5. Release proﬁles of resiquimod-loaded microparticles (MPs) composed of acetalate
starting material molecular weights (MW) incubated at pH 7.4 (A–C) and 5.0 (D–F). Thnitrite production with respect to blank MP-treated controls
(Fig. 7). For cells incubated with 10 kDa MPs of different CAC, lower
nitrite production was observed with higher CAC. This inverse
relationship between nitrite production and polymer CAC can be
explained by different release kinetics of MPs with varying CAC
(Fig. 5). Because MPs of higher CAC hydrolyzed slower under acidic
conditions (Table 3), they likely released a smaller intraphagoso-
mal amount of resiquimod after phagocytosis, resulting in less
robust nitrite production. This trend was less obvious for 71 kDa
MPs because 71 kDa Ace-DEX degraded faster than 10 kDa. By the
end of the incubation period, most of the 71 kDa MPs that had been
phagocytosed by macrophages were nearly completely degraded,
minimizing the effect of varying CAC.
When polymer CAC was held constant (40%), nitrite production
was in general more potent for higher MW MPs. MPs fashioned
from 500 or 2000 kDa dextran induced greater nitrite production
than those formulated using polymer of lower MW. This trend may
be due to different release proﬁles of resiquimod from MPs
composed of varying dextran MW. A larger amount of resiquimod
may be released after phagocytosis for higher MW MPs due to their
faster hydrolysis (Table 3 and Fig. 5), resulting in more robust
nitrite production. Therefore, macrophage activation and nitrite
production can be precisely controlled by CAC and MW of Ace-DEX
MPs, which makes Ace-DEX an ideal carrier for therapeutic
delivery.d dextran (Ace-DEX) with different relative cyclic acetal coverage (CAC) and dextran
e solid lines are sigmoidal functions added as a visual guide.
Fig. 7. Nitrite production by RAW macrophages incubated with free or encapsulat-
ed resiquimod (resi) after 24 or 48 h. Resiquimod was encapsulated by acetalated
dextran (Ace-DEX) microparticles (MPs) with varying dextran molecular weight
and relative cyclic acetal coverage. Resiquimod concentration for all treatment
groups was 0.15 mg/mL. Blank Ace-DEX (10 kDa, 60%) MP control is at the highest
particle concentration (0.23 mg/mL). Lipopolysaccharide (LPS, 100 ng/mL) was used
as the positive control. Data are presented as mean  standard deviation (n = 3).
Statistical signiﬁcance with respect to blank MPs is presented as *p < 0.05 and
**p < 0.005. Statistical signiﬁcance with respect to free resiquimod is presented as
yp < 0.05 and yyp < 0.005.
Fig. 6. (A) Cellular metabolic activity and (B) cytotoxicity of RAW macrophages incubated with resiquimod-loaded acetalated dextran (Ace-DEX) microparticles (MPs) for 24
or 48 h. Resiquimod (resi) concentration for all treatment groups was 0.15 mg/mL. Blank Ace-DEX (10 kDa, 60%) MP control is at the highest particle concentration (0.23 mg/
mL). Lipopolysaccharide (LPS, 100 ng/mL) was used as the positive control. Data are presented as mean  standard deviation (n = 3).
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We have shown that Ace-DEX MPs with lower CAC or higher
dextran MW hydrolyzed faster under both physiologically neutral
pH 7.4 and phagosomal pH 5.0, with degradation half-lives being
much shorter under acidic conditions, compared to those with
higher CAC or lower MW. The facile tunability of Ace-DEX
chemistry allowed for both burst and sustained long-term release
of encapsulated therapeutics using the same polymeric platform,
which makes Ace-DEX an ideal material for particle formulation.
Overall, acid-sensitivity, tunable degradation, pH neutral metab-
olites, and minimal toxicity on macrophages in culture make Ace-
DEX advantageous over existing acid-sensitive polymeric systems
and a promising candidate for particle formulation and therapeutic
delivery. Future work exploring the degradation proﬁles of Ace-
DEX polymers of varying CAC and MW at intermediate pH levels
will further characterize the tunability of this platform. Scalableproduction and in vivo efﬁcacy of Ace-DEX MPs will also be studied
to further demonstrate the novelty and advantages of this polymer
system.
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